2 results
Approved WMOCompleted
To evaluate the pharmacodynamic (PD) effects of daridorexant 25mg, 50mg, and placebo in the middle-of-the-night.
Approved WMOPending
Objectives• To evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn*s disease• To assess the overall safety of guselkumabPrimary EndpointThe primary endpoint of this study is the proportion of participants who achieve combined…